According to a report from Vaporvoice, United States Senators Joe Manchin, Rand Paul, and Ted Budd have jointly written a letter to the Center for Tobacco Products (CTP) of the Food and Drug Administration (FDA), urging it to reform the pre-market tobacco product application (PMTA) process. Additionally, they have requested the center to provide information regarding policies and actions taken to ensure that its actions are grounded in science and evidence and conducted in an effective manner.
A report highlights that "smoking is a leading cause of preventable diseases and deaths in the United States, with approximately 31 million Americans being smokers," wrote the senators in their letter. "In order to achieve the Food and Drug Administration's goal of reducing harm, an effective authorization process must be in place.
Since 2009, more than 26 million PMTA applications for new products have been submitted in the United States. However, the Center for Tobacco Products (CTP) has only approved less than 50 of these applications. Senators argue that availability of scientifically backed and authorized PMTA or MRTP could potentially improve the health conditions of current smokers using risky tobacco products.
Senators mentioned that in order to achieve the goal of preventing harm to public health, the FDA must have an effective authorization process. Additionally, they also stated that the FDA's authorization speed is far from acknowledging the risk levels of tobacco products.
Senators wrote in a letter, "Previously, CTP attributed its backlog of work to staff shortage, but over the past decade, the number of employees at CTP has grown from 426 in 2013 to over 1,100 now.
According to them, since 2009, the FDA has had the authority to assess and collect user fees from tobacco manufacturers and importers, with these fees reaching $712 million per year since 2019. "With such substantial resources, there should be no reason for the CTP to be incapable of complying with the requirements of the Food, Drug, and Cosmetic Act.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
